open access

Vol 90, No 6 (2019)
RECOMMENDATIONS
Published online: 2019-06-28
Get Citation

Treatment guidelines for acquired hemophilia A

Jerzy Windyga, Beata Baran, Edyta Odnoczko, Anna Buczma, Krzysztof Drews, Piotr Laudanski, Bronislawa Pietrzak, Piotr Sieroszewski
DOI: 10.5603/GP.2019.0063
·
Pubmed: 31276188
·
Ginekol Pol 2019;90(6):353-364.

open access

Vol 90, No 6 (2019)
RECOMMENDATIONS
Published online: 2019-06-28

Abstract

Not available

Abstract

Not available
Get Citation
About this article
Title

Treatment guidelines for acquired hemophilia A

Journal

Ginekologia Polska

Issue

Vol 90, No 6 (2019)

Pages

353-364

Published online

2019-06-28

DOI

10.5603/GP.2019.0063

Pubmed

31276188

Bibliographic record

Ginekol Pol 2019;90(6):353-364.

Authors

Jerzy Windyga
Beata Baran
Edyta Odnoczko
Anna Buczma
Krzysztof Drews
Piotr Laudanski
Bronislawa Pietrzak
Piotr Sieroszewski

References (51)
  1. Knoebl P, Marco P, Baudo F, et al. EACH2 Registry Contributors. Demographic and clinical data in acquired hemophilia A: results from the European Acquired Haemophilia Registry (EACH2). J Thromb Haemost. 2012; 10(4): 622–631.
  2. W Collins P, Chalmers E, Hart D, et al. United Kingdom Haemophilia Centre Doctors' Organization. Diagnosis and management of acquired coagulation inhibitors: a guideline from UKHCDO. Br J Haematol. 2013; 162(6): 758–773.
  3. Scandella D, Mattingly M, de Graaf S, et al. Localization of epitopes for human factor VIII inhibitor antibodies by immunoblotting and antibody neutralization. Blood. 1989; 74(5): 1618–1626.
  4. Collins PW, Percy CL. Advances in the understanding of acquired haemophilia A: implications for clinical practice. Br J Haematol. 2010; 148(2): 183–194.
  5. Buczma A, Windyga J. Nabyta hemofilia. Pol. Arch. Med. Wew. 2007: 5–6, 241–245.
  6. Collins P, Macartney N, Davies R, et al. A population based, unselected, consecutive cohort of patients with acquired haemophilia A. Br J Haematol. 2004; 124(1): 86–90.
  7. Collins PW, Hirsch S, Baglin TP, et al. UK Haemophilia Centre Doctors' Organisation. Acquired hemophilia A in the United Kingdom: a 2-year national surveillance study by the United Kingdom Haemophilia Centre Doctors' Organisation. Blood. 2007; 109(5): 1870–1877.
  8. Green D, Lechner K. A survey of 215 non-hemophilic patients with inhibitors to Factor VIII. Thromb Haemost. 1981; 45(3): 200–203.
  9. Kessler C, Nemes L. Acquired inhibitors to factor VIII. In: Rodriguez-Merchan EC, Lee CA. ed. Inhibitors in patients with hemophilia. Blackwell Science, Oxford 2002: 98–114.
  10. Windyga J. Acquired hemophilia. J Transf Med. 2010; 4: 131–132.
  11. Acquired factor VIII inhibitors in pregnancy: data from the Italian Haemophilia Register relevant to clinical practice. BJOG: An International Journal of Obstetrics and Gynaecology. 2003; 110(3): 311–314.
  12. Tengborn L, Baudo F, Huth-Kühne A, et al. EACH2 registry contributors. Pregnancy-associated acquired haemophilia A: results from the European Acquired Haemophilia (EACH2) registry. BJOG. 2012; 119(12): 1529–1537.
  13. Hauser I, Schneider B, Lechner K. Post-partum factor VIII inhibitors. A review of the literature with special reference to the value of steroid and immunosuppressive treatment. Thromb Haemost. 1995; 73(1): 1–5.
  14. Michiels JJ. Acquired hemophilia A in women postpartum: clinical manifestations, diagnosis, and treatment. Clin Appl Thromb Hemost. 2000; 6(2): 82–86.
  15. Lulla RR, Allen GA, Zakarija A, et al. Transplacental transfer of postpartum inhibitors to factor VIII. Hemophilia. 2009; 15: 1166–1168.
  16. Kasper CK, Pool JG. Letter: Measurement of mild factor VIII inhibitors in Bethesda units. Thromb Diath Haemorrh. 1975; 34(3): 875–876.
  17. Odnoczko E, Baran B, Windyga J. Z hemostazą na Ty. BioKsel, 2016 .
  18. Windyga J. Diagnostyka laboratoryjna zaburzeń hemostazy. In: Mariańska B, Fabijańska-Mitek J, Windyga J. ed. Badania laboratoryjne w hematologii. Podręcznik dla słuchaczy studiów medycznych. Wyd. Lek. PZWL, Warszawa 2003: 192–225.
  19. Sallah S. Treatment of acquired haemophilia with factor eight inhibitor bypassing activity. Haemophilia. 2004; 10(2): 169–173.
  20. Ehrlich HJ, Henzl MJ, Gomperts ED. Safety of factor VIII inhibitor bypass activity (FEIBA): 10-year compilation of thrombotic adverse events. Haemophilia. 2002; 8(2): 83–90.
  21. Depka MV. NovoSeven: mode of action and use in acquired haemophilia. Intensive Care Medicine. 2002; 28(0): s222–s227.
  22. Baudo F, et al. Management of bleeding in acquired hemophilia A: results from the European Acquired Hemophilia (EACH2) Registry. Blood. 2012; 120: 39–46.
  23. Zanon E, Pasca S, Santoro C, et al. Activated prothrombin complex concentrate (FEIBA ) in acquired haemophilia A: a large multicentre Italian study - the FAIR Registry. Br J Haematol. 2019; 184(5): 853–855.
  24. Borg JY, Négrier C, Durieu I, et al. FEIBHAC Study Group. FEIBA in the treatment of acquired haemophilia A: results from the prospective multicentre French 'FEIBA dans l'hémophilie A acquise' (FEIBHAC) registry. Haemophilia. 2015; 21(3): 330–337.
  25. Windyga J, Chojnowski K, Klukowska A, et al. Część II: Wytyczne postępowania w hemofilii A i B powikłanej inhibitorem czynnika VIII i IX (2 wydanie). Acta Haematologica Polonica. 2017; 48(3): 137–159.
  26. Gringeri A, Fischer K, Karafoulidou A, et al. European Haemophilia Treatment Standardisation Board (EHTSB). Sequential combined bypassing therapy is safe and effective in the treatment of unresponsive bleeding in adults and children with haemophilia and inhibitors. Haemophilia. 2011; 17(4): 630–635.
  27. Kruse-Jarres R, Kempton CL, Baudo F, et al. Acquired hemophilia A: Updated review of evidence and treatment guidance. Am J Hematol. 2017; 92(7): 695–705.
  28. Tarantino MD, Cuker A, Hardesty B, et al. Recombinant porcine sequence factor VIII (rpFVIII) for acquired haemophilia A: practical clinical experience of its use in seven patients. Haemophilia. 2017; 23(1): 25–32.
  29. Huth-Kühne A, Baudo F, Collins P, et al. International recommendations on the diagnosis and treatment of patients with acquired hemophilia A. Haematologica. 2009; 94(4): 566–575.
  30. Windyga J, Chojnowski K, Klukowska A, et al. W imieniu Grupy Roboczej ds. Hemostazy Polskiego Towarzystwa Hematologów i Transfuzjologów. Polskie zalecenia postępowania w nabytej hemofilii A. Medycyna Praktyczna. 2011; 10: 1–8.
  31. Windyga J, et al. Activated prothrombin complex concentrate in combination with tranexamic acid: a single center experience for the treatment of mucosal bleeding and dental extraction in hemophilia patients with inhibitors. Hemophilia. 2016; 22: e465–e468.
  32. Valentino LA, Holme PA. Should anti-inhibitor coagulant complex and tranexamic acid be used concomitantly? Haemophilia. 2015; 21(6): 709–714.
  33. Narodowy Program Leczenia Chorych na Hemofilię i Pokrewne Skazy Krwotoczne. https://www.gov.pl/documents.
  34. Collins PW, et al. Immunosuppression for acquired hemophilia A: results from the European Acquired Hemophilia Registry (EACH2). Blood. 2012; 120: 47–55.
  35. Green D, Rademaker AW, Briët E. A prospective, randomized trial of prednisone and cyclophosphamide in the treatment of patients with factor VIII autoantibodies. Thromb Haemost. 1993; 70(5): 753–757.
  36. Kessler CM, Acs P, Mariani G. Acquired disorders of coagulation: the immune coagulopthies. In: Colman RW, Marder VJ, Clowes AW, George JN, Goldhaber SZ. ed. Hemostasis and thrombosis. Basic principles and clinical practice. Fifth edition. Lippincott Williams & Wilkins, Philadelphia 2006: 1061–1084.
  37. GREEN D. The management of acquired haemophilia. Haemophilia. 2006; 12(s5): 32–36.
  38. Delgado J, Jimenez-Yuste V, Hernandez-Navarro F, et al. Acquired haemophilia: review and meta-analysis focused on therapy and prognostic factors. Br J Haematol. 2003; 121(1): 21–35.
  39. Aggarwal A, Grewal R, Green RJ, et al. Rituximab for autoimmune haemophilia: a proposed treatment algorithm. Haemophilia. 2005; 11(1): 13–19.
  40. D’Arena G, et al. The anti-CD20 monoclonal antibody rituximab to treat acquired hemophilia A. Blood Transfus. 2016; 14: 255–261.
  41. Bonfanti C, Crestani S, Frattini F, et al. Role of rituximab in the treatment of postpartum acquired haemophilia A: a systematic review of the literature. Blood Transfus. 2015; 13(3): 396–400.
  42. Sborov DW, Rodgers GM. How I manage patients with acquired haemophilia A. Br J Haematol. 2013; 161(2): 157–165.
  43. Schulman S, Langevitz P, Livneh A, et al. Cyclosporine therapy for acquired factor VIII inhibitor in a patient with systemic lupus erythematosus. Thromb Haemost. 1996; 76(3): 344–346.
  44. Lian ECY, Villar MJo, Noy LI, et al. Acquired factor VIII inhibitor treated with cyclophosphamide, vincristine, and prednisone. Am J Hematol. 2002; 69(4): 294–295.
  45. Obaji S, Rayment R, Collins P. Mycophenolate mofetil as adjunctive therapy in acquired haemophilia A. Haemophilia. 2018; 25(1): e59–e65.
  46. McFadyen JD, Tran H, Kaplan ZS. Factor VIII inhibitor eradication with bortezomib in acquired haemophilia A. Br J Haematol. 2017; 178(6): 986–987.
  47. Nemes L, Pitlik E. Ten years experience with immune tolerance induction therapy in acquired hemophilia. Hematologica. 2003; 88(suppl. 12): 64–68.
  48. Zanon E, Pasca S, Siragusa S, et al. FAIR Study Group. Low dose of aPCC after the initial treatment in acquired haemophilia A is useful to reduce bleeding relapses: Data from the FAIR registry. Thromb Res. 2019; 174: 24–26.
  49. Baudo F, de Cataldo F. Italian Association of Haemophilia Centres (AICE): Register of acquired factor VIII inhibitors (RIIA). Acquired factor VIII inhibitors in pregnancy: data from the Italian Haemophilia Register relevant to clinical practice. BJOG. 2003; 110(3): 311–314.
  50. Coller BS, Hultin MB, Hoyer LW, et al. Normal pregnancy in a patient with a prior postpartum factor VIII inhibitor: with observations on pathogenesis and prognosis. Blood. 1981; 58(3): 619–624.
  51. Solymoss S. Postpartum acquired factor VIII inhibitors: results of a survey. Am J Hematol. 1998; 59(1): 1–4.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk
tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl